Beijing GoBroad Hospital Management

GoBroad Healthcare Group is a leading clinical research-driven hospital group in China, specializing in hematology, oncology, and immunotherapy. Founded in 2017 and backed by Hillhouse Capital, the group operates a network of research-oriented hospitals, including Beijing Boren Hospital and Shanghai GoBroad Cancer Hospital. GoBroad is renowned for its expertise in chimeric antigen receptor T-cell (CAR-T) therapy and hematopoietic stem cell transplantation, serving as a major site for innovative clinical trials. The company integrates clinical care with advanced diagnostic and research capabilities through its unique Academic Research Organization (ARO) model to provide personalized treatment for complex cancers and autoimmune diseases. With over 470 ongoing clinical trials, GoBroad serves as a critical bridge between basic scientific research and industrial transformation in the biopharmaceutical sector.